Abstract 427P
Background
Angiosarcomas are a rare subtype of soft-tissue sarcomas which exhibit aggressive clinical phenotypes with limited treatment options and poor outcomes.
Methods
In this study, we investigated the clinical relevance of the peripheral blood neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic immune response, as well as its correlation with intra-tumoral immune profiles using the NanoString PanCancer IO360 panel and multiplex immunohistochemistry.
Results
In the overall cohort (n=150), angiosarcomas of the head and neck comprised most cases (58.7%) and median overall survival (OS) was 1.1 year. NLR, classified as high in 78 of 112 (70%) evaluable patients, was independently correlated with worse OS (HR 1.84, 95%CI 1.18-2.87, p=0.0073), along with age >65 years and distant metastasis at diagnosis. Peripheral blood NLR was positively correlated with intra-tumoral NLR (tNLR) (Spearman’s rho 0.450, p=0.0067). Visualization of tumor-infiltrating immune cells confirmed that tNLR scores correlated directly with both neutrophil (CD15+ cells, rho 0.398, p=0.0198) and macrophage (CD68+ cells, rho 0.515, p=0.0018) cell counts. Interestingly, tNLR correlated positively with oncogenic pathway scores including angiogenesis, matrix remodelling & metastasis and cytokine & chemokine signaling, as well as myeloid compartment scores (all p<0.001). In patients with documented best clinical responses to first-line chemotherapy (n=60), these pathway scores were all significantly higher in non-responders (47%) compared to responders.
Conclusions
These findings suggest that systemic and local immune responses may inform clinical outcomes in angiosarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
SingHealth Duke-NUS Oncology ACP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session